Introduction/Background Our aim was to assess the effect of various modifications of neoadjuvant chemotherapy (NACT) on the overall five-year survival (OS) of patients with locally advanced cervical cancer (LACC) with the inclusion of therapeutic plasmapheresis (PA) and nonspecific immunotherapy in the treatment programme.

Methodology As the first stage of treatment of 51 patients with LACC of T2a-2bN0-1M0 stages, NACT courses were performed according to the scheme: cisplatin and bleocin.

The first group consisted of the patients (n=31) who underwent a session of PA, a day after which they started a course of NACT. A course of nonspecific immunotherapy with Allokin-alpha was performed in parallel with the course of NAPCT.

The second group consisted of 20 patients who received standard NACT scheme: cisplatin, bleomycin.

Results Among the studied groups, the maximum OS was observed in the patients of the second group who received PA, courses on NAPCT and immunomodulator Allokin-alpha.

In this group, OS was 83.5±4.6%; which is much higher than the rates of OS in the group of patients treated according to the standard method (50.6±6.6%).

The differences are statistically significant, p=0.0462 (Log-Rank test).

Conclusion Carrying out NACT in combination with PA and nonspecific immunotherapy in the treatment of patients with LACC is pathogenetically justified, since it allows to heighten the effect of cytostatics on the tumor, has an immunomodulatory effect on the body of patients and significantly increases the overall 5-year survival of patients.

Disclosure Nothing to disclose.